Therapeutic vaccine candidate for the treatment of advanced
PROSTVAC® is a therapeutic vaccine candidate in Phase 3
clinical development that has the potential to significantly extend
the lives of men with advanced prostate cancer.
The vaccine is administered subcutaneously and induces a
specific, targeted immune response that attacks metastatic cells in
the prostate. Conventional chemotherapy currently used to treat
prostate cancer has limited survival rates and is often associated
with numerous side effects.
PROSTVAC® has been subject of 13 completed and 6 ongoing
clinical trials involving more than 850 patients.
A Phase 3 trial (PROSPECT) in 1,200 patients with asymptomatic
or minimally symptomatic castration-resistant prostate cancer was
initiated in November 2011, expected to form the basis for approval
of the vaccine for this patient population.
Information about the Phase 3 PROSPECT trial can be found
More about PROSTVAC®